Cargando…
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
BACKGROUND: The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC). METHODS: Protein expression of n...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493874/ https://www.ncbi.nlm.nih.gov/pubmed/23099809 http://dx.doi.org/10.1038/bjc.2012.463 |
_version_ | 1782249342325751808 |
---|---|
author | Myklebust, M P Li, Z Tran, T H Rui, H Knudsen, E S Elsaleh, H Fluge, Ø Vonen, B Myrvold, H E Leh, S Tveit, K M Pestell, R G Dahl, O |
author_facet | Myklebust, M P Li, Z Tran, T H Rui, H Knudsen, E S Elsaleh, H Fluge, Ø Vonen, B Myrvold, H E Leh, S Tveit, K M Pestell, R G Dahl, O |
author_sort | Myklebust, M P |
collection | PubMed |
description | BACKGROUND: The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC). METHODS: Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses. RESULTS: Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to surgery alone in colon cancer (P=0.012 and P=0.038, respectively) and especially in colon cancer stage III patients (P=0.005 and P=0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS (P=0.004) and CSS (P=0.025) in multivariate analysis. CONCLUSION: Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/LEV treatment in colon cancer, particularly in stage III colon cancer. |
format | Online Article Text |
id | pubmed-3493874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-34938742013-11-06 Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer Myklebust, M P Li, Z Tran, T H Rui, H Knudsen, E S Elsaleh, H Fluge, Ø Vonen, B Myrvold, H E Leh, S Tveit, K M Pestell, R G Dahl, O Br J Cancer Clinical Study BACKGROUND: The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC). METHODS: Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses. RESULTS: Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to surgery alone in colon cancer (P=0.012 and P=0.038, respectively) and especially in colon cancer stage III patients (P=0.005 and P=0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS (P=0.004) and CSS (P=0.025) in multivariate analysis. CONCLUSION: Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/LEV treatment in colon cancer, particularly in stage III colon cancer. Nature Publishing Group 2012-11-06 2012-10-25 /pmc/articles/PMC3493874/ /pubmed/23099809 http://dx.doi.org/10.1038/bjc.2012.463 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Myklebust, M P Li, Z Tran, T H Rui, H Knudsen, E S Elsaleh, H Fluge, Ø Vonen, B Myrvold, H E Leh, S Tveit, K M Pestell, R G Dahl, O Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer |
title | Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer |
title_full | Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer |
title_fullStr | Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer |
title_full_unstemmed | Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer |
title_short | Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer |
title_sort | expression of cyclin d1a and d1b as predictive factors for treatment response in colorectal cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493874/ https://www.ncbi.nlm.nih.gov/pubmed/23099809 http://dx.doi.org/10.1038/bjc.2012.463 |
work_keys_str_mv | AT myklebustmp expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT liz expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT tranth expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT ruih expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT knudsenes expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT elsalehh expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT flugeø expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT vonenb expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT myrvoldhe expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT lehs expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT tveitkm expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT pestellrg expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer AT dahlo expressionofcyclind1aandd1baspredictivefactorsfortreatmentresponseincolorectalcancer |